Physician profile
James Michael Alberto Bell
NPI 1447767397
$4,675.91
in general payments reported to CMS, 2019-2025
16 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $287 · 2023: $292 · 2024: $2,324 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,388.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $839.91 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $682.76 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $524.98 | 2023-2025 | Sotyktu |
| Abbvie INC. | $417.18 | 2023-2025 | Rinvoq |
| Ucb, INC. | $404.75 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $320.57 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $313.50 | 2024-2025 | Tremfya |
| Janssen Biotech, INC. | $265.46 | 2023-2025 | Tremfya |
| Leo Pharma INC. | $172.99 | 2025 | Adbry, Anzupgo |
| Incyte Corporation | $151.01 | 2024-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $146.82 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $143.97 | 2024 | Vtama |
| Pfizer INC. | $132.36 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $109.61 | 2024-2025 | Dupixent |
| Genzyme Corporation | $26.00 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $24.04 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Michael Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.